Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Tropism of retinal infectiity of novel AAV serotypes in mice
Author Affiliations & Notes
  • Wenjing Lily wu
    Ophthalmology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
  • Joel McRae
    Ophthalmology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
  • Martin-Paul Gameli Agbaga
    Ophthalmology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
    Cell Biology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
  • Footnotes
    Commercial Relationships   Wenjing Lily wu None; Joel McRae None; Martin-Paul Agbaga None
  • Footnotes
    Support  American Macular Degeneration Foundation (AMDF), R01EY030513, R21AR076035
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2201. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Wenjing Lily wu, Joel McRae, Martin-Paul Gameli Agbaga; Tropism of retinal infectiity of novel AAV serotypes in mice. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2201.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Adeno-associated viruses (AAVs) are the viral vectors of choice for ophthalmological gene therapy research as they have been proven to be efficient for long-term gene expression in retinal cells. However, AAV-mediated retinal cell transduction efficiency is limited due to the specificity of cell surface receptor requirement for transduction by the various viral serotypes. Advances in AAV capsid optimization to improve cell tropism have led to the engineering of synthetic hybrid AAV capsid vectors that mediate widespread transgene expression in retinal cells. However, these novel candidates have not been compared side by side. To identify AAV serotypes that mediate efficient retinal transduction and gene expression to rescue inherited retinal degenerative diseases, we compared the efficiency of retinal cell transduction of four novel AAV serotypes in adult WT mice after intraocular delivery

Methods : Four different AAV-CMV-GFP hybrid serotypes were tested in vivo in 2-month-old WT mice. 1.0 ul of 1x10^12 GC/ml of each viral particle was delivered into mouse eyes either by intravitreal or subretinal injection. At 1-month and 3-month post injections, the tropism of each serotype to efficiently transduce retinal cells was examined using GFP transgene expression in photoreceptor (PR) and RPE cells by fundoscopy, fluorescence microscopy, and histology

Results : Fundoscopy and immunohistological analysis of GFP levels in the retina showed that mice injected with AAVDJ and AAVDJ8 had the highest GFP fluorescence. Subretinal injection resulted in all serotypes successfully transducing PR and RPE cells with AAVDJ8 and AAVDJ exhibiting the highest transduction and GPF expression efficiency. With intravitreal injection, AAV2-7m8 and AAVDJ serotypes led to efficient PR transduction, while AAVDJ8 exhibited the highest RPE transduction. Visual function showed no differences between all the serotypes injected

Conclusions : We found that novel synthetic AAV serotypes differentially transduce both the inner and outer retinal cell layers depending on the method of intraocular delivery. Of the four serotypes studied, AAVDJ8 seems to be the most effective at transducing both PR and RPE cells when injected intravitreally. Because intravitreal injection is less invasive and is often utilized on human subjects, novel AAV capsids capable of successfully transducing PR and RPE cells by intravitreal delivery would transform the retinal gene therapy landscape

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×